Cargando…

Pre‐transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors

BACKGROUND: The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate pre‐HSCT strategies by comparing the endpoints...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yu‐Qian, Xu, Lan‐Ping, Liu, Kai‐Yan, Zhang, Xiao‐Hui, Yan, Chen‐Hua, Jin, Jian, Huang, Xiao‐Jun, Wang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045915/ https://www.ncbi.nlm.nih.gov/pubmed/33566460 http://dx.doi.org/10.1002/cac2.12140

Ejemplares similares

Appropriate pre-transplant strategy for patients with myelodysplastic syndromes receiving allogeneic haematopoietic stem cell transplantation after myeloablative conditioning
por: Wang, Hong, et al.
Publicado: (2023)

Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome
por: Chung, Yang Jo, et al.
Publicado: (2017)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Sirolimus and Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation
por: Johnston, L, et al.
Publicado: (2011)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Second Hematopoietic Stem Cell Transplantation for Leukemia Relapsing after Myeloablative T Cell Depleted Transplants Does Not Prolong Survival
por: McIver, Zachariah A., et al.
Publicado: (2013)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
por: Zhenyang, Gu, et al.
Publicado: (2021)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study
por: Chang, Ying-Jun, et al.
Publicado: (2020)

Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
por: Servais, Sophie, et al.
Publicado: (2015)

Does Kidney Transplantation With Deceased or Living Donor Affect Graft Survival?
por: Nemati, Eghlim, et al.
Publicado: (2014)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Pre-transplant Evaluation of Donor Urinary Biomarkers can Predict Reduced Graft Function After Deceased Donor Kidney Transplantation
por: Koo, Tai Yeon, et al.
Publicado: (2016)

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
por: Treister, Nathaniel, et al.
Publicado: (2017)

Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning
por: Wagner, John E., et al.
Publicado: (2021)

Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor
por: Sun, Yu-Qian, et al.
Publicado: (2021)

Reliability of Pre-Transplant Live Donor Renal Biopsies in Predicting the Graft Outcome
por: Naderi, G. H., et al.
Publicado: (2014)

Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission
por: Walter, Roland B., et al.
Publicado: (2010)

Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report
por: Hamilton, Betty K, et al.
Publicado: (2013)

Feasibility of using marginal liver grafts in living donor liver transplantation
por: Lan, Xiang, et al.
Publicado: (2018)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Pilot experience with opebacan/rBPI (21) in myeloablative hematopoietic cell transplantation
por: Guinan, Eva, et al.
Publicado: (2015)

The Risk of Cytomegalovirus Infection in Non-myeloablative Peripheral Stem Cell Transplantation Compared with Conventional Bone Marrow Transplantation
por: Oh, Suk Joong, et al.
Publicado: (2004)

Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Survival Benefit of Living-Donor Liver Transplant
por: Jackson, Whitney E., et al.
Publicado: (2022)

P1269: PRIMARY GRAFT FAILURE INCIDENCE, RISK FACTORS, AND OUTCOMES IN PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION USING POST-TRANSPLANT CYCLOPHOSPHAMIDE
por: Mata, Jonaphine, et al.
Publicado: (2023)

Does Living Donor Hyperoxia Have an Impact on Kidney Graft Function After Transplantation?
por: Rostami, Zohreh, et al.
Publicado: (2013)

Graft survival after living donor transplantation
por: Mani, M. K.
Publicado: (2011)

Unusual grafts for living-donor liver transplantation
por: Yim, Seung Hyuk, et al.
Publicado: (2023)

Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm
por: Rieger, Max J., et al.
Publicado: (2023)

A gut microbiota score predicting acute graft‐versus‐host disease following myeloablative allogeneic hematopoietic stem cell transplantation
por: Han, Lijie, et al.
Publicado: (2019)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor
por: Forlenza, Christopher J., et al.
Publicado: (2015)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
por: van Balen, Peter, et al.
Publicado: (2018)

The effects of myeloablative or non-myeloablative total body irradiations on intestinal tract in mice
por: Zhu, Shengyun, et al.
Publicado: (2021)

Donor Death Category Is an Effect Modifier Between Cold Ischemia Time and Post-transplant Graft Function in Deceased-Donor Kidney Transplant Recipients
por: Luo, You, et al.
Publicado: (2021)

Liver Transplantation With Grafts From Super Obese Donors
por: Vargas, Paola A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_97p6el8dqbom4gs10mo6kp8258